Quick answer: ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) is a serious neuroimmune disease affecting an estimated 1–2.5 million Americans, characterized by post-exertional malaise (PEM) — the hallmark symptom — along with profound fatigue, orthostatic intolerance, cognitive dysfunction, and unrefreshing sleep. ME/CFS is not psychosomatic and is not treated by graded exercise therapy (GET), which worsens the majority of patients. The current understanding involves mitochondrial dysfunction, impaired cellular energy production, dysregulated HPA and autonomic nervous system function, reactivated latent herpesvirus infections (EBV, HHV-6), and metabolomic abnormalities in the TCA cycle and amino acid catabolism pathways. The functional approach focuses on: pacing (avoiding PEM triggers), mitochondrial support (CoQ10, D-ribose, NADH, magnesium malate), low-dose naltrexone for neuroinflammation, orthostatic intolerance management, and targeted immune support.
ME/CFS Is Not Chronic Fatigue: Why This Distinction Matters
Persistent fatigue is an extremely common symptom — it affects a large percentage of the general population and is a component of many medical conditions. ME/CFS is different in kind, not just in degree. The distinguishing feature is post-exertional malaise (PEM): a worsening of all symptoms — cognitive, physical, and neurological — that is triggered by physical or cognitive exertion that would have been previously tolerated, with a characteristic delay of 12–48 hours after the triggering activity and a recovery period of days to weeks. PEM is pathognomonic for ME/CFS and is what distinguishes it from depression, hypothyroidism, sleep disorders, and other fatiguing conditions where exercise typically improves symptoms.
The 2015 National Academy of Medicine (IOM) report “Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness” concluded that ME/CFS is a serious, chronic, complex, systemic disease that often profoundly affects patients’ lives. The report established new diagnostic criteria (now called SEID — Systemic Exertion Intolerance Disease in the IOM framework) and explicitly stated that ME/CFS requires systemic attention and recognition as a disease, not a psychiatric condition. The 2023 NIH research initiative (RECOVER) has expanded this understanding by identifying objective biomarkers in ME/CFS and Long COVID — conditions that share overlapping pathophysiology.
Diagnostic Criteria: The Canadian Consensus and IOM Criteria
The Canadian Consensus Criteria (2003) and the IOM/SEID criteria (2015) are the two most clinically validated frameworks. The IOM criteria require: (1) substantial reduction in functional capacity lasting more than 6 months; (2) post-exertional malaise; (3) unrefreshing sleep; and (4) either cognitive impairment or orthostatic intolerance. The Canadian Consensus Criteria add specific requirements for pain, neurological/cognitive, and autonomic manifestations, and are preferred by many ME/CFS specialists for their greater clinical specificity.
What these criteria explicitly exclude: the original “Oxford criteria” that required only 6 months of unexplained fatigue (now considered too broad and no longer recommended) and the “Fukuda criteria” that were widely used for research but are considered insufficiently specific. Critically, the IOM criteria do NOT include exercise intolerance as a criterion — they require PEM specifically, which is exertion-triggered relapse, not simply fatigue with exercise. This distinction is important because it filters out many conditions that cause exercise intolerance but do not have the PEM pattern.
The Biology of ME/CFS: What the Research Shows
Mitochondrial Dysfunction and Impaired Cellular Energy Production
Multiple lines of evidence implicate mitochondrial dysfunction as a central mechanism in ME/CFS. Naviaux et al. (2016) identified a metabolomic profile in ME/CFS patients consistent with a hypometabolic state — reduced metabolite concentrations across the TCA cycle, sphingolipid metabolism, and amino acid catabolism pathways, suggesting a sustained cellular defense response that downregulates energy production. This “dauer-like” state (analogous to the dormancy response triggered in C. elegans under stress) reduces ATP production capacity and is associated with elevated lactate at lower workloads, reduced VO2 max on cardiopulmonary exercise testing, and impaired ability to repeat peak oxygen consumption on day-2 CPET (a finding specific to ME/CFS that differentiates it from deconditioning).
The 2-day CPET (cardiopulmonary exercise test) finding is particularly important: in healthy sedentary people, peak VO2 is reproducible on day 1 and day 2 of testing. In ME/CFS patients, peak VO2 drops 20–30% on day 2 — a finding not seen in depression, fibromyalgia, or deconditioning. This objective measurement provides biological evidence for PEM and explains why graded exercise therapy worsens ME/CFS: pushing through the energy ceiling accelerates the mitochondrial crash rather than building tolerance.
Reactivated Herpesvirus Infections
ME/CFS frequently begins after an acute viral infection — Epstein-Barr virus (EBV) mononucleosis, HHV-6, enteroviruses, and most recently SARS-CoV-2 (Long COVID). Approximately 10% of patients with documented EBV or enterovirus infection develop ME/CFS-like symptoms that persist beyond 6 months. This viral triggering pattern suggests that in susceptible individuals, acute infection triggers a persistent immune and neurological response. Elevated titers to EBV early antigen (EA), viral capsid antigen (VCA), and HHV-6 antibodies are common in ME/CFS patients, suggesting ongoing immune stimulation from reactivated latent viruses rather than fresh reinfection. Antiviral therapy (valacyclovir at high doses for EBV, valganciclovir for HHV-6) has produced improvement in subsets of ME/CFS patients with clear herpesvirus reactivation — but this is a specialist decision requiring proper viral load assessment.
Orthostatic Intolerance and Autonomic Dysfunction
Orthostatic intolerance is present in up to 97% of ME/CFS patients and is a major — often underappreciated — driver of symptoms. Two forms are most common in ME/CFS: POTS (Postural Orthostatic Tachycardia Syndrome — heart rate increases ≥30 bpm or rises above 120 bpm within 10 minutes of standing) and NMH (Neurally Mediated Hypotension — blood pressure drops paradoxically upon standing despite initial tachycardia). Both reduce cerebral blood flow, producing the characteristic brain fog, difficulty standing, worsening symptoms in warm environments, and “crash” after mild physical activity. The orthostatic intolerance component of ME/CFS is frequently missed because blood pressure and heart rate are measured only while the patient is seated in the office.
Proper assessment requires a 10-minute standing test (continuous heart rate monitoring while standing from seated position) or formal tilt-table testing. Treatment for orthostatic intolerance in ME/CFS: increased sodium and fluid intake (3–5g sodium/day, 2.5–3L fluid/day), compression garments (waist-high or abdominal binders), head-of-bed elevation to 10–20 degrees (to recalibrate baroreceptors overnight), and careful medication management (fludrocortisone or beta-blockers in refractory cases under physician supervision).
Neuroinflammation
Neuroimaging studies using PET scanning have demonstrated microglial activation (a marker of brain inflammation) in ME/CFS patients compared to controls — particularly in the cingulate cortex, thalamus, and hippocampus, regions associated with cognitive function, pain modulation, and fatigue processing. Cerebrospinal fluid studies have identified elevated cytokines, altered protein profiles, and evidence of CNS inflammation. This neuroinflammatory state likely underlies the cognitive symptoms (brain fog, memory impairment, difficulty with word-finding and multitasking) and contributes to the central sensitization that amplifies pain and fatigue signaling.
The Most Important Treatment Principle: Pacing
Pacing — managing activity to stay within the energy envelope and avoid triggering PEM — is the single most important ME/CFS management strategy and should be the first and non-negotiable foundation of any treatment plan. The energy envelope theory: each ME/CFS patient has a maximum sustainable activity level above which PEM is triggered. Staying consistently below this threshold prevents PEM, allows gradual recovery, and is associated with better long-term outcomes than attempts to push through symptoms.
Heart rate monitoring (using a heart rate monitor during all activities) provides an objective guide to staying within the aerobic threshold. The anaerobic threshold in ME/CFS is typically well below predicted values — often calculated as (220 – age) × 0.5 to 0.6. Keeping heart rate below this threshold during all activities (including cognitive tasks — which raise heart rate in ME/CFS patients) prevents the mitochondrial crash that triggers PEM. Pacing also applies to cognitive and emotional activity — intense concentration, social interactions, and emotional stress consume the same limited energy as physical activity.
Functional Medicine Interventions with Evidence
Mitochondrial Support Stack
Given the evidence for impaired mitochondrial energy production, several targeted nutritional interventions are used in ME/CFS. Coenzyme Q10 (CoQ10) — 300–600 mg/day of ubiquinol form — is the most evidence-supported single intervention for ME/CFS fatigue: a 2012 RCT showed significant improvements in fatigue and autonomic function at 200 mg CoQ10 + 20 mg NADH daily. CoQ10 is consistently low in ME/CFS patients. NADH (10–20 mg/day as Enada/stabilized NADH) — the reduced form of NAD+ that directly drives ATP synthesis — provides substrate for Complex I of the electron transport chain. D-ribose (5g 3x/day) — the 5-carbon sugar that is rate-limiting for ATP resynthesis — produced significant improvements in fatigue, sleep, mental clarity, and wellbeing in a 2006 open-label trial of ME/CFS and fibromyalgia patients. Magnesium malate (300–400 mg magnesium equivalent, twice daily) — malate supports the TCA cycle, and magnesium deficiency impairs ATP synthesis; injectable magnesium sulfate (the “Myers’ cocktail” intravenous formula) has a long history of use in ME/CFS and fibromyalgia. L-carnitine (2g/day) transports long-chain fatty acids across the mitochondrial membrane for beta-oxidation — deficiency is documented in ME/CFS.
Low-Dose Naltrexone (LDN)
Low-dose naltrexone (1.5–4.5 mg at bedtime, compared to the 50 mg standard dose for addiction treatment) is one of the most promising pharmacological interventions in ME/CFS and fibromyalgia. At low doses, naltrexone acts as a TLR4 antagonist on microglial cells, reducing neuroinflammation — and transiently blocks opioid receptors for a few hours, triggering a rebound upregulation of endorphin production. The net effect is reduced neuroinflammation, improved pain modulation, and improved immune regulation. Multiple case series and pilot trials show significant improvements in ME/CFS symptoms with LDN, including fatigue, cognitive function, and pain. LDN must be obtained through a compounding pharmacy and requires a physician prescription, but is increasingly prescribed by ME/CFS specialists and functional medicine practitioners.
Sleep Architecture Restoration
Unrefreshing sleep is a diagnostic criterion for ME/CFS — patients often experience prolonged sleep time but wake feeling unrestored, suggesting disrupted sleep architecture (particularly insufficient slow-wave/deep sleep) rather than insufficient total sleep. Low-dose melatonin (0.5–1 mg, not the conventional high doses) helps entrain circadian rhythm without suppressing natural melatonin production. Magnesium glycinate before bed specifically increases slow-wave sleep percentage. For patients with comorbid delayed sleep phase syndrome (common in ME/CFS), careful light therapy in the morning and light avoidance in the evening can help normalize the circadian rhythm that ME/CFS frequently disrupts. Sleep-disordered breathing (sleep apnea) should be ruled out in all ME/CFS patients — it is underdiagnosed and significantly worsens ME/CFS.
Orthostatic Intolerance Management
As described above, orthostatic intolerance is present in the vast majority of ME/CFS patients and is a significant contributor to symptoms. Addressing it can produce meaningful functional improvement. The non-pharmacological approach: increased sodium and fluid intake (3–5g sodium/day from sea salt added to food and drinks — important: not a sodium restriction, as in most cardiovascular recommendations), 2.5–3L fluid/day, waist-high compression garments, head-of-bed elevation (4–6 inches), frequent small meals rather than large meals (which divert blood to the gut and worsen cerebral blood flow), and avoiding prolonged standing. Slow, recumbent exercise (swimming, recumbent biking) is preferable to upright exercise for patients with significant POTS, as it minimizes orthostatic stress while providing the cardiovascular benefits of Zone 2 training.
What to Avoid: Treatments That Worsen ME/CFS
Graded exercise therapy (GET) was the primary treatment recommendation for ME/CFS for decades, based on the theoretical model that “deconditioning” perpetuated illness and that gradually increasing exercise would restore function. Multiple patient surveys, prospective studies, and ultimately the PACE trial reanalysis have demonstrated that GET worsens ME/CFS in a significant proportion of patients (estimates range from 50–80% report worsening). The biological basis: PEM is not a deconditioning phenomenon — it is a mitochondrial crash triggered by exertion that exceeds the energy threshold. Pushing through PEM does not build tolerance; it depletes ATP reserves and triggers the immune-neurological cascade that produces the multi-day relapse. GET has been removed from UK NICE guidelines (updated 2021) as a recommended treatment for ME/CFS.
Cognitive Behavioral Therapy (CBT) for ME/CFS (as practiced in the PACE trial model — specifically the model that posits cognitive distortions about activity perpetuate illness) is similarly problematic. This CBT model explicitly encourages patients to disregard PEM, which leads to crashes and worsening. CBT for symptom management, psychological support, and comorbid depression and anxiety is appropriate and helpful — but CBT designed to override PEM-protective behaviors is harmful. This is a nuanced distinction that requires careful communication.
Stimulants (including high-dose caffeine) in the absence of pacing create a “boom-bust” cycle: artificially extended activity periods followed by severe PEM crashes. Patients often use caffeine to push through fatigue, which temporarily masks the energy threshold signals and leads to significant PEM. Caffeine in small doses with meals is fine; using stimulants to override the body’s signals for rest is counterproductive.
The Overlap with Long COVID
The post-COVID condition (Long COVID) shares extensive clinical and biological overlap with ME/CFS — including PEM, brain fog, orthostatic intolerance, unrefreshing sleep, and dysregulated immune function. Many researchers and clinicians now consider Long COVID to be ME/CFS triggered by SARS-CoV-2, with the same underlying biology (viral trigger → persistent immune activation → mitochondrial dysfunction → neuroinflammation) as other post-infectious ME/CFS cases. The NIH RECOVER initiative has confirmed that PEM is one of the most common and disabling Long COVID symptoms and has explicitly adopted the ME/CFS management framework for Long COVID patients with PEM.
This convergence is both validating for ME/CFS patients (who struggled for decades to have their illness recognized as biological) and practically important: the mitochondrial support, LDN, orthostatic intolerance management, and pacing strategies validated in ME/CFS apply directly to Long COVID patients with the PEM pattern.
The Bottom Line
ME/CFS is a serious, biologically complex neuroimmune disease with objective abnormalities in mitochondrial function, autonomic regulation, immune activation, and cerebral blood flow. It is not psychosomatic, and the primary historical treatment recommendation (graded exercise therapy) worsens the majority of patients. The evidence-based functional approach begins with pacing (non-negotiable), addresses orthostatic intolerance (present in 97% of patients), supports mitochondrial energy production (CoQ10, NADH, D-ribose, magnesium malate, L-carnitine), and reduces neuroinflammation (LDN). Reactivated viral infections should be assessed in patients with clear infectious onset. Sleep architecture must be optimized. This is a field evolving rapidly, particularly as Long COVID research validates the ME/CFS biology and accelerates treatment development.
If you have been experiencing profound fatigue with post-exertional malaise, brain fog, unrefreshing sleep, and orthostatic symptoms — particularly after a viral infection — a comprehensive functional medicine evaluation is the appropriate starting point for understanding the underlying biology and implementing targeted interventions. Call our office at (810) 206-1402 to schedule a consultation focused on complex chronic illness and neuroimmune conditions.
Frequently Asked Questions
What is the difference between CFS and ME/CFS?
The terms are used interchangeably today. “CFS” (Chronic Fatigue Syndrome) was the original US term, while “ME” (Myalgic Encephalomyelitis) was the original UK/international term. The combined “ME/CFS” reflects current recognition that these names describe the same condition. The 2015 IOM report proposed “SEID” (Systemic Exertion Intolerance Disease) as a more accurate name reflecting the core pathophysiology — post-exertional malaise — but ME/CFS remains the most widely used clinical and research term. The condition is the same regardless of which name is used.
What causes chronic fatigue syndrome?
ME/CFS typically begins after an acute trigger — most commonly a viral infection (EBV/mononucleosis, HHV-6, enteroviruses, COVID-19), but also surgery, physical trauma, or severe psychological stress. In susceptible individuals, this trigger initiates a persistent immune-neurological response characterized by: reactivated latent herpesvirus infections, mitochondrial energy production dysfunction, HPA axis dysregulation, autonomic nervous system dysfunction (orthostatic intolerance), and neuroinflammation. Why some people develop ME/CFS after infections while others recover normally is an active area of research — genetic susceptibility, prior viral history, and immune regulatory differences appear to play roles.
Is there a cure for ME/CFS?
There is no established cure for ME/CFS as of 2026. The most validated management approach focuses on pacing to prevent PEM crashes, mitochondrial support, orthostatic intolerance treatment, and neuroinflammation reduction (LDN). Some patients achieve significant functional improvement and sustained remission with comprehensive functional medicine management — particularly those with identified treatable secondary causes (e.g., reactivated EBV responding to antivirals, POTS responding to sodium/fluid management, sleep apnea corrected by CPAP). The Long COVID research surge is accelerating ME/CFS treatment development, with multiple clinical trials underway examining antivirals, anti-inflammatory agents, and immunomodulatory therapies.
Does exercise help or hurt ME/CFS?
The answer depends entirely on whether PEM is present and whether the exercise stays below the energy threshold. Graded exercise therapy (GET) — the traditional approach of gradually increasing exercise intensity regardless of PEM — worsens ME/CFS in the majority of patients and has been removed from UK NICE guidelines as a recommended treatment. What helps: paced, heart-rate-monitored activity that stays below the anaerobic threshold (approximately 50-60% of maximum heart rate), recumbent exercise for patients with orthostatic intolerance (swimming, recumbent cycling), and gentle movement during good days without pushing to exhaustion. The principle is maintaining function without triggering PEM — not building exercise capacity through progressive overload, as in healthy individuals.